English Extended Distribution Financial Content iCN Internal Distribution Press Release Reportedtimes Research Newswire

Metastatic Renal cell Carcinoma (mRCC) to Reach USD 7.9 Billion in 2030 with a CAGR of 7.5%

Metastatic Renal cell Carcinoma (mRCC) is expected to see a high growth during our forecast period. The market in the G7 countries is expected to reach USD 7.9 billion in 2030 with a CAGR of 7.5%. Primary drivers of this growth will be the uptake of the emerging drugs i.e., Belzutifan (Merck/Peloton Therapeutics), Bempegaldesleukin (Bristol-Myers Squibb/Nektar Therapeutics), and others.

The renal cell carcinoma market has witnessed a substantial change, largely fueled by label expansions of immune checkpoint inhibitor therapies. Combination regimens, including Opdivo plus Yervoy (Bristol Myers Squibb / Ono Pharmaceutical), Keytruda (Merck & Co.) plus Inlyta (Pfizer), and Bavencio (Pfizer / Merck KGaA) plus Inlyta, are revolutionizing the treatment of advanced disease. The recent approval and uptake of the Opdivoplus Cabometyx (Exelixis / Ipsen) and axitinib plus pembrolizumab combination will also drive fierce competition in this setting. Multiple immune checkpoint inhibitors are also anticipated to enter the early-stage setting over the forecast period. Additionally, the anticipated entry of other agents such as bempegaldesleukin (NektarTherapeutics) and belzutifan (Merck & Co.) will further diversify treatment options and create a highly competitive and dynamic market.


The current treatment market has long been dominated by targeted treatments, including mTOR and angiogenesis inhibitors. However, the introduction of immune checkpoint inhibitors has diversified treatment options and the treatment landscape for renal cell carcinoma market is rapidly moving toward combination combinatorial approaches. The introduction of diagnostic companions could offer the possibility of providing better outcomes and reducing the cost-burden of patients that are less likely to respond to the therapy.

Read More: https://www.giiresearch.com/report/mell1043373-metastatic-renal-cell-carcinoma-mrcc-primary.html


Tags: Kidney Cancer, AstraZeneca, Dovitinib, Bempegaldesleukin, Belzutifan, National Cancer Institute, mRCC, Metastatic Renal Cell Carcinoma

See Campaign: https://www.giiresearch.com/topics/ph31/

Contact Information:

Global Information, Inc. (JASDAQ 4171) https://www.giiresearch.com/ Toll Free (US): +1-866-353-3335 Outside US: +1-860-674-8796 Europe (Belgium): +32-2-535-7543 Email: marketing@giiresearch.com

Reportedtimes, Financial Content, Extended Distribution, iCN Internal Distribution, Research Newswire, English